By Hannah Critchfield
A generic version of the HIV prevention drug Truvada is coming. Also known as PrEP, it’s the only drug known to prevent HIV, and since its invention in 2012 only one company has been allowed to produce it. Earlier this week its manufacturer Gilead Sciences announced it would allow another company, Teva, to make a generic version of PrEP in 2020.
I spoke to Christopher Morten, a patent lawyer at the Global Health Justice Partnership at Yale Law School, about what a little competition might mean for consumers.